Supplemental Tables and Figures
Supplemental Table 1. Characteristics of participants in each trial.
Supplemental Table 2. Adjusted risk for kidney and death outcomes by each trial.
Supplemental Table 3. Additional analyses examining interactions between randomized BP assignment and eGFR as a continuous variable.
Supplemental Figure 1. Unadjusted risk of the kidney outcome in each trial.
Supplemental Table 1. Characteristics of participants in each individual study.
N (%) unless otherwise
noted AASK ACCORD ESCAPE MDRD REIN 2 SPRINT SPS3 Total
N=959 N=499 N=326 N=821 N=307 N=2,506 N=405 N=5,823
Predominant Cause of CKD
Hypertensive
Disease Diabetes
Obstructive uropathy and
glomerulo- nephritis
Non-diabetic CKD
Non-diabetic CKD
Non-diabetic
CKD Unknown
RAS blockade Randomized Per
investigator All Per
investigator All Per
investigator Per investigator Median follow-up in parent
trial 3.7 years 4.7 years 4.4 years 2.2 years 1.8 years 3.3 years 3.7 years
Age at randomization
Mean ± SD 54.0 ± 10.7 67.0 ± 6.7 11.8 ± 4.0 51.8 ± 12.4 54.8 ± 14.7 72.8 ± 9.1 69.5 ± 11.3 61.6 ± 18.2
Women 383 (39.9) 276 (55.3) 135 (41.4) 321 (39.1) 78 (25.4) 976 (38.9) 184 (45.4) 2,353 (40.4)
Black race 959 (100.0) 90 (18.0) 0 (0.0) 65 (7.9) 0 (0.0) 657 (26.2) 67 (16.5) 1,838 (31.6)
eGFR (mL/min/1.73 m2)
mean ± SD 40.1 ± 11.6 51.1 ± 7.2 32.4 ± 13.6 32.1 ± 11.8 28.9 ± 12.0 47.0 ± 9.8 51.3 ± 6.7 42.6 ± 12.7 Urine albumin/creatinine
ratio (mg/g) median ( IQR)* 16.3 (5.1,
173) 19.5 (7.7, 82) 254.5 (50,
722) 212.0 (46,
908) 1432.0 (908
2198) 14.0 (6.6, 46) --- 29 (8.1,
239.7) Systolic Blood Pressure
(mmHg) mean ± SD 150.3 ± 24.0 141.0 ± 17.0 110.4 ± 15.4 131.8 ± 15.6 137.0 ± 17.1 139.4 ± 16.1 148.0 ± 20.8 139.1 ± 20.1 Diastolic Blood Pressure
(mmHg) mean ± SD 95.3 ± 14.3 72.7 ± 10.8 64.5 ± 12.9 80.6 ± 8.7 84.3 ± 9.8 74.5 ± 12.2 77.8 ± 11.4 78.8 ± 14.5
Diabetes 0 (0.0) 499 (100.0) 0 (0.0) 43 (5.2) 17 (5.5) 0 (0.0) 149 (36.8) 708 (12.2)
CKD Stage 4 or 5 222 (23.2) 4 (0.8) 148 (45.4) 366 (44.6) 170 (55.4) 170 (6.8) 0 (0) 1080 (18.6)
Achieved SBP (mmHg) 135.9 ± 13.7 129.5 ± 12.4 ---- 129.9 ± 14.5 132.5 ± 11.8 129.2 ± 11.0 133.8 ± 11.2 131 ± 12.6
*UACR not available in SPS3; Achieved SBP not reported in ESCAPE trial due to age and sex-specific absolute percentiles in children
Supplemental Table 2. Effect of intensive BP control on kidney and death outcomes in each individual trial.
Kidney outcome Death prior to ESKD
N events Adjusted Hazard ratio (95% CI)
N events Adjusted Hazard ratio (95% CI)
AASK 177 1.00 (0.74-1.35) 80 0.89 (0.57-1.39)
ACCORD 22 0.54 (0.21-1.36) 54 1.07 (0.62-1.83)
ESCAPE** 62 0.78 (0.46-1.30) 0 ---
MDRD 154 0.75 (0.55-1.03) 20 1.75 (0.70-4.40)
REIN2 71 1.03 (0.63-1.69) 5 0.65 (0.10-4.24)
SPRINT 16 0.56 (0.20-1.56) 161 0.77 (0.56-1.05)
SPS3 24 1.17 (0.49-2.82) 62 0.79 (0.47-1.32)
*Adjusted for age, sex, black race, baseline eGFR, logarithm of urine albumin/creatinine ratio, and diabetes allowing for baseline hazard to differ across different cohorts.
**There are no deaths available for inclusion in ESCAPE trial
Supplemental Table 3. Additional sensitivity analyses examining interactions between randomized BP assignment and eGFR as a continuous variable accounting for between- and within-trial differences.
Comparison of eGFR interaction analyses
Hazard ratio or p-value Unadjusted Hazard ratio
Adjusted for covariates and trial data source
Adjusted for trial data source and interactions between all covariates and trial data source Not centered Centered Not centered Centered Not centered Centered
Coefficient for interaction term 1.016 1.03 1.014 1.022 1.0144 1.020
P-value for interaction 0.052 0.004 0.105 0.037 0.09 0.056
Supplemental Figure 1. Effect of intensive BP control on the primary kidney outcome by individual trials in unadjusted analysis.
